GLP-1 weight management
Mounjaro
tirzepatide / pronounced [tir zep' a tide]
FDA-approved tirzepatide for type 2 diabetes. Off-label for weight loss is common.
- Manufacturer
- Eli Lilly
- FDA approved
- 2022
- Pivotal efficacy
- 2.0–2.3% HbA1c reduction across SURPASS trials (15 mg dose) · SURPASS-2 (NCT03987919) — vs semaglutide
FDA-approved for
- Type 2 diabetes
FDA Boxed Warning
Risk of thyroid C-cell tumors. Tirzepatide causes thyroid C-cell tumors in rats. Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Why is Mounjaro prescribed?
Mounjaro is FDA-approved for type 2 diabetes. Same active ingredient as Zepbound (tirzepatide). Off-label weight-loss use is common, particularly where Zepbound supply is constrained.
FDA-approved indications:
- Type 2 diabetes
How does Mounjaro work?
Same as Zepbound — dual GLP-1/GIP receptor agonist. Strong glycemic effect plus weight loss.
Who qualifies for Mounjaro?
FDA indication: type 2 diabetes glycemic control. Off-label weight-loss prescribing depends on platform/clinician judgment.
How should Mounjaro be used?
Titrated 2.5mg → 15mg weekly over months, same schedule as Zepbound.
What should I do if I forget a dose?
Mounjaro is dosed once weekly. If missed: take within 4 days of scheduled day, then resume regular schedule. If more than 4 days late, skip and continue. Do not double up. T2D patients should check blood sugar more frequently if a dose was missed.
How effective is Mounjaro?
2.0–2.3% HbA1c reduction across SURPASS trials (15 mg dose)
- Trial:
- SURPASS-2 (NCT03987919) — vs semaglutide
- Comparator:
- Tirzepatide 15 mg achieved 2.30% HbA1c reduction vs 1.86% for semaglutide 1 mg
- Participants:
- n = 1,879
What side effects can Mounjaro cause?
Same as Zepbound.
What interactions should clinicians watch for?
Same tirzepatide interaction profile as Zepbound. Most clinically meaningful: insulin and sulfonylureas (hypoglycemia risk when combined — typical T2D regimen requires dose adjustment), oral contraceptives (delayed absorption — manufacturer recommends non-oral or barrier method for 4 weeks after each dose escalation), warfarin (closer INR monitoring during titration). No major interactions with statins, antihypertensives, or thyroid medications at standard doses.
What special precautions should I follow?
Pregnancy & lactation
Mounjaro is not recommended during pregnancy. Discontinue at least 1-2 months before planned pregnancy (tirzepatide half-life ~5 days plus margin). For T2D patients planning pregnancy, transition to pregnancy-safe diabetes management (insulin, metformin) before conception. Not recommended while breastfeeding. The oral contraceptive interaction is a real fertility-planning consideration if pregnancy is not desired.
Alcohol
No formal contraindication. T2D patients should be mindful of combined hypoglycemia risk with alcohol (especially if also on insulin or sulfonylureas). Slowed gastric emptying changes alcohol absorption. Moderate amounts may be acceptable for stable patients; check with your endocrinologist for personalized guidance.
What does Mounjaro cost?
Similar to Zepbound — list ~$1,000/month, LillyDirect Self-Pay $399-549/month.
In case of emergency or overdose
Same molecule as Zepbound; same overdose guidance. No specific antidote. Half-life ~5 days. Call US Poison Control at 1-800-222-1222 immediately or seek emergency care for severe hypoglycemia (especially in T2D patients on insulin or a sulfonylurea), persistent vomiting, dehydration signs, or altered mental status. Bring the pen + packaging to the ER if you go.
How should Mounjaro be stored?
Refrigerate Mounjaro at 36°F to 46°F (2°C to 8°C) until first use. After first use, may be stored at room temperature up to 86°F (30°C) for up to 21 days. Do not freeze. Protect from light.
Primary sources
- [1] FDA-approved Mounjaro (tirzepatide) prescribing information
- [2] SURPASS-2: Tirzepatide vs semaglutide once weekly in type 2 diabetes (NEJM, 2021)
- [3] SURPASS-5: Tirzepatide added to titrated insulin glargine for type 2 diabetes (JAMA, 2022)
- [4] Eli Lilly Mounjaro prescribing site
- [5] ADA Standards of Care in Diabetes — pharmacologic therapy for adults with T2D
Related clinical resources
What clinicians say
Quotes from published interviews, peer-reviewed commentary, and conference presentations. Each is attributed and linked to the original source.
“In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks.”
Source: New England Journal of Medicine — SURPASS-2 trial publication (Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes) (August 2021 — DOI 10.1056/NEJMoa2107519)
“Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether tirzepatide causes such tumors, including medullary thyroid carcinoma, in humans. Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2.”
Source: FDA-approved Mounjaro (tirzepatide) prescribing information — current label (Approved May 2022; current label 2022)